Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. (PHIO) on April 22, 2025, reporting events occurring on April 17, 2025. The Company is incorporated in Delaware and trades on The Nasdaq Capital Market. The filing primarily addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it notes that the independent auditor's reports for the fiscal years ended December 31, 2024, and December 31, 2023, included an explanatory paragraph relating to substantial doubt about the Company's ability to continue as a going concern.
Material Changes
- Dismissal of Auditor: The Audit Committee approved the dismissal of BDO USA, P.C. as the independent registered public accounting firm, effective immediately on April 17, 2025.
- Engagement of New Auditor: The Audit Committee approved the engagement of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately on April 17, 2025.
- Board Ratification: The Board of Directors ratified the Audit Committee's decisions regarding the dismissal and engagement.
Guidance, Risks, and Contingencies
The filing confirms there were no disagreements with the former auditor, BDO, regarding accounting principles, practices, financial statement disclosures, or auditing scope/procedures during the fiscal years ended December 31, 2024 and 2023, or the interim period through April 17, 2025. Additionally, no reportable events as described under Item 304(a)(1)(v) of Regulation S-K occurred during these periods. The Company has not consulted Grant Thornton regarding matters referred to in Item 304(a)(2)(i) or (ii) of Regulation S-K prior to this engagement.
Investor Verification Checklist
- Verify the "substantial doubt about going concern" status mentioned in the 2023 and 2024 audit reports and assess current liquidity positions.
- Review the letter from BDO USA, P.C. (Exhibit 16.1) to confirm their agreement with the statements regarding the dismissal.
- Monitor upcoming financial filings to ensure the transition to Grant Thornton LLP does not impact the timeliness of future reporting.
- Confirm the Company's progress in resolving the going concern issues identified by the previous auditor.